Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: AÂ randomized, double-blind, placebo-controlled, patient-initiated clinical trial

ME-609 prevented progression of cold sores to ulcerative lesions and significantly reduced the cumulative lesion area compared with acyclovir and placebo. ME-609 treatment offers additional therapeutic benefit compared with therapy with topical acyclovir alone.